Ipamorelin and Longevity and Anti-Aging: What Has Been Studied

What the research covers

No published study was found that tested ipamorelin for ageing or lifespan. Human data come from a dosing study in healthy men and trials after bowel surgery. Ipamorelin is a lab-made peptide, five amino acids long, that triggers the release of growth hormone (GH). It acts on the ghrelin receptor.

In a dosing study, healthy men got a 15-minute infusion at one of five doses, eight men per dose. GH rose in a single peak at about 40 minutes, then fell to very low levels at every dose. The drug had a half-life of 2 hours. A phase 2 trial gave ipamorelin or placebo by IV to adults after bowel surgery. The dose was 0.03 mg per kilogram twice a day, for up to 7 days. Of 117 patients enrolled, 114 were analysed. Ipamorelin was well tolerated but did no better than placebo. A second phase 2 trial, in 320 bowel surgery patients, is listed as completed with no results posted.

In a rodent (rat) study, young adult females got ipamorelin at 0.5 mg per kilogram a day for 12 weeks. Body weight and bone mineral content rose. Bone mineral per unit of body weight did not change. The bones grew larger, not denser by volume. In pigs, ipamorelin did not raise the stress hormones ACTH or cortisol beyond what GHRH did. These hormone results come from pigs, not people.

A PubMed search on 27 September 2026 found no study of ipamorelin and ageing or lifespan. In the published human trial, dosing lasted up to 7 days. No long-term human safety data were found.

Sources

1. Gobburu JV, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res (1999). PMID 10496658 doi:10.1023/a:1018955126402
2. Beck DE, Sweeney WB, McCarter MD Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis (2014). PMID 25331030 doi:10.1007/s00384-014-2030-8
3. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol (1998). PMID 9849822 doi:10.1530/eje.0.1390552
4. Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol (2000). PMID 10828840 doi:10.1677/joe.0.1650569